1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6D7053389DFC352F30025859F00641298
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-how-medical-affairs-teams-use-RWE-utilization-investment-roi?opendocument
18
19opendocument
203.228.10.64
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Data Management and Biostatics

How Medical Affairs Teams Use RWE: Utilization, Investment and ROI

ID: 5624


Features:

9 Info Graphics

24 Data Graphics

200+ Metrics

4 Narratives


Pages/Slides: 40


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "How Medical Affairs Teams Use RWE: Utilization, Investment and ROI"

STUDY OVERVIEW

The power of real world evidence (RWE) has significantly increased demand for outcomes and other RWE insights across the entire healthcare value chain, from thought leaders and HCPs to payers and regulatory bodies.

In response, pharmaceutical and medical device companies are taking steps to increase the precision and speed of their RWE capabilities. This trend has impacted Medical Affairs since pharma already relies on this function to lead many of the medical aspects of RWE utilization.

This study evaluates the role of Medical Affairs in real world evidence utilization, investment and performance measurement. This study will inform Medical Affairs leaders regarding the current trends and practices of medical regarding RWE utilization, investment and ROI.


KEY TOPICS

  • Real World Evidence in 2020 and Beyond
  • Real World Data Utilization & Evidence Generation
  • Real World Evidence Investment
  • KPIs and Measuring Organizational RWE Performance

KEY METRICS

1. Improvements to Medical Affairs’ use of real world data

  • Best practices followed by Medical Affairs groups in developing RWE
  • Current use of real world data vs. utilization of real world data in the next two years
  • Use of real world data in health economic outcomes, disease & patients insights, and payers/ formulary influencers activities
  • Use of real world data in clinical trials and physicians related activities
  • Emerging applications of RWE and anticipated increase in their usage over the next two years among companies using
  • Success factors for highly prioritized real world data/evidence activities
  • Future usage of real world data – Health economic outcomes, disease & patients, and payers/
  • formulary influencers
  • Future usage of real world data - Clinical Trial Related, and physicians
  • Barriers limiting Medical Affairs real world evidence generation
  • Use of real world data within large companies and small-mid sized companies
2. Real World Evidence Investment
  • The next three years; primary drivers of changes in the RWE budget
  • Top prioritized RWE innovations for investment
  • Change in RWE budget in next three years - Distribution by company size
  • Total budget allocated to real world data and evidence generation in 2020 by benchmark companies
  • Percentage of real world data collected from internal, external, and external (free data) sources
  • Proportion of RWE budget allocated to internal RWE generation vs. externally driven RWE generation
3. KPIs and Measuring Organizational RWE Performance
  • Use of KPIs to measure the success of real world data program
  • Performance measurement areas for real world data/evidence
  • Currently used publication-based KPIs
  • Number of publications utilizing real world data
  • Impact of currently used KPIs
  • Currently used engagement-related and general KPIs
  • Performance measurement areas for real world data/evidence – publications, engagement, general, and impact
  • Future use of KPIs
SAMPLE KEY FINDINGS
  • RWE Use: Medical use of RWE/D is expanding – with clinical trial related and disease insight/patient profiling areas seeing strongest advance. Seek to expand RWE utilization in alignment with the external stakeholder groups most influential to your orgs. TA/disease state

METHODOLOGY

Best Practices engaged 45 industry leaders across 36 companies to discern RWD/E best practices, trends, and Medical Affairs optimal role.

Industries Profiled:
Pharmaceutical; Health Care; Medical Device; Biotech; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Novartis; Merck; EMD Serono; Roche; AstraZeneca; Astellas; Merck Serono; Takeda Pharmaceuticals; Sanofi; Boehringer Ingelheim; Teva Pharmaceutical Industries Ltd; Eisai; Jazz Pharmaceuticals; Grifols; Edwards Lifesciences; OTSUKA; Vertex Pharmaceuticals; Terumo Corporation; UCB Pharma; Avanos Medical; GE Healthcare; Fidia; Intercept; CSPC Pharmaceutical Group; Invitae; Cipla; Proteus Digital Health; Agios; Almirall; Adamas Pharmaceuticals; Dendreon; Purdue Pharma; Searle; ADC Therapeutics; Mitsubishi Tanabe Pharma; Melinta Therapeutics; Inc

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.